
Lyon, France
Human neuronal models for drug development.
NETRI combines microfluidic cell culture, electrophysiology and data analysis to study how human neurons respond to drugs and other compounds.
The drugmaker problem
Pain, CIPN, and neurotox are still decided on the wrong animal.
Chemotherapy-induced neuropathy, pain, chemical neurotoxicity, and neurodegeneration are human nerve problems. The usual assays are a rodent, or a dish that cannot fire like a network.
Drugs, chemicals and cosmetics all need to be assessed for their effects on human nerves. Human neuronal models can provide more relevant answers than animal studies alone.
What they do
NETRI.
NETRI builds nerve-on-chip and neuron-as-a-sensor organ-on-chip platforms — NeuroFluidics and related systems — so human neural networks can live on a microfluidic chip and give a readable signal.
The work is pain, chemotherapy-induced peripheral neuropathy, neurotoxicity, neurodegeneration, and CNS. A human-relevant alternative to animal testing for pharma, chemical, and cosmetics companies.
Why you would use it
Where human neuronal models inform drug development.
- 01
Chemotherapy-induced peripheral neuropathy and pain
Assess whether chemotherapies and drug candidates affect the structure and electrical activity of human sensory neurons.
- 02
Neurotoxicity
Evaluate the effects of drugs, chemicals and cosmetic ingredients on the function of human neuronal networks, complementing in vivo safety studies.
- 03
Neurodegeneration and CNS
Measure functional readouts such as electrical activity and network connectivity in human neuronal models of central nervous system disease.
Who it is for
Pharma, chemical, and cosmetics teams — and the CROs and academics who support them — who need a human alternative to animal testing for nerve decisions.
Collaborations and programmes
NETRI is working with several pharmaceutical companies to evaluate its chemotherapy-induced neuropathic pain model. Public partners and programs are listed below.

Compartmentalized models with MEA electrophysiology. Collaboration since 2022; NeuroFluidics MEA launched in 2023.
Joined the 3DEXPERIENCE Lab in 2026 to digitalize production and experimental processes.

TEER measurements with MultiFluidics platforms, including EVOM 3.

Human iPSC-derived neuronal cells in compartmentalized platforms, since 2022.

BIO-DIAMOND project on neurodegenerative disease models, under France 2030.

Human cellular systems integrated into preclinical workflows.
Computing for large-scale electrophysiological data analysis.
Cloud infrastructure for storing and analyzing experimental data.
Pesticide neurotoxicity.
Startup Ally of the MDSS programme, 2026.
On the board
RocketBio holds a board seat and supports business development.
Considering the next chapter for your business?
We welcome conversations with owners of established scientific tools and technology businesses who are considering a long-term partner.
